Thalidomide for prevention of camrelizumab‐induced reactive cutaneous capillary endothelial proliferation

por Song, Geng, Zhang, Fei‐Fei, Cheng, Huai‐Dong
Publicado 2022

B7-H3 is eligible for predicting clinical outcomes in lung adenocarcinoma patients treated with EGFR tyrosine kinase inhibitors

por Yang, Ying, Huang, Jun-feng, Hu, Bing-qi, Zhou, Jing, Wang, Xian, Feng, Zhen-zhong, Chen, Yu-ting, Pan, Fa-ming, Cheng, Huai-dong, Chen, Li-wen
Publicado 2022